- Display 15 Products per page
Published: April 1, 2006 | Price: $3,500.00 – $7,000.00
Adjunctive therapies are not only vital to the success of cancer treatments, enhancing compliance and outcomes, but they are also a dynamic area of research and development in a variety of disciplines from drug delivery to biologics. It also happens to be the largest portion of the overall cancer therapeutics market. This report provides the reader with a comprehensive analysis of the worldwide market for therapeutics to treat and manage symptoms in cancer patients. Market information, including market size and...Published: April 1, 2006 | Price: $2,500.00 – $7,000.00
The landscape of generic companies is changing: their relative might in the industry is increasing and the product lines their offering are growing in depth and breadth. Strong growth in the sector has come not only from more aggressive tactics and better acceptance in the clinical and consumer population, but by the loss of patent protection in the past few years of some huge-name drugs, including Prozac, Zocor, Prilosec, Prevacid, Sporanox, Evista, Flovent, Claritin, Allegra, Diflucan, Zofran, Zoloft, and Pravachol....Published: March 1, 2006 | Price: $3,500.00 – $7,000.00
There are hundreds of drugs in Phase III clinical trials, of which almost 200 of them may gain market approval from the FDA in the coming 5 years. Which drugs will make it and how these drugs impact existing pharmaceutical markets in terms of overall size and competitive share is one of the most difficult forecasting projects in market research. In this nearly 500-page analysis, Kalorama Information has compiled all the relevant information about the candidates, their value, and their...Published: March 1, 2006 | Price: $3,500.00 – $7,000.00
The strategic interplay of of HIV/AIDS diagnostics and therapeutics is one of the most complex that the healthcare industry has ever seen. In order to cope with the challenges and opportunities of HIV/AIDS, companies must think on a global basis, and in addition to the basic pathology and complications of HIV/AIDS, there are societal and ethical pressures, geopolitical factors, and evolving marketplace disruptions. For the development of a coherent strategy in this therapeutic area, companies must clearly focus on three...Published: February 18, 2006 | Price: $2,200.00 – $5,990.00
Biopharmaceutical research and development is sure to dramatically increase the number of injectable drugs coming to market over the next few years. While advanced drug delivery techniques continue to hold promise for unique methods of administration, the traditional injection is still the dominant paradigm. However, the staggering costs and intransigent safety problems associated with sharps, along with consumer demand and the move to alternate-site care, are pushing for alternatives to traditional needles and syringes faster than advanced delivery technologies can...Published: February 1, 2006 | Price: $1,995.00 – $7,800.00
This report provides the reader with a comprehensive analysis of the domestic and international markets involving pharmaceuticals to treat skin diseases and disorders. This edition of Worldwide Market for Prescription Dermatologic Drugs is the fifth time Kalorama Information has comprehensively studied the dermatology markets. As is the case with each new edition, Kalorama completely re-evaluated the market from the ground up, and in addition to the usual primary interviewing of industry participants, clinicians, and regulators, we also conducted scores of...Published: February 1, 2006 | Price: $3,000.00 – $6,000.00
The private label over-the-counter (OTC) market has been gaining ground rapidly over the past five years. The private label sector has shed its image of being a ‘me-too’ version of national brands and worked toward offering quality and innovation at an economical price. With benefits for consumers, retailers, and manufacturers, private label healthcare should experience solid growth through the end of the decade. This report on the U.S. market for OTC private label products presents an in-depth analysis of the...Published: January 1, 2006 | Price: $995.00 – $5,990.00
With the mapping of the human genome and the concomitant explosion of proteomics, a steady stream of biopharmaceuticals have been launched—recombinant therapeutic proteins, monoclonal antibody-based products used for therapeutic or in vivo diagnostic purposes, and nucleic acid-based products. As the rate of regulatory approval for biopharmaceuticals increases, the number of products reaching the market will impose unprecedented demands on the industry’s biomanufacturing capacity. Whether or not this will create a biomanufacturing bottleneck is a hotly debated issue in the industry....Published: January 1, 2006 | Price: $2,995.00 – $5,990.00
In the Spring of 2003, Kalorama published its first report on Outsourcing in Drug Discovery. Since then, so much has changed, the use of the term "2nd Edition" hardly seems appropriate. This new study involved completely re-examining the market from the ground up. This new report is designed to make readers aware of the enormous changes that are taking place in the drug discovery outsourcing market, and the forces that are shaping the sector. It presents viewpoints from both customers...Published: January 1, 2006 | Price: $3,000.00 – $6,000.00
The U.S. Market for OTC anti-infective products surpassed the $2 billion mark last year. Although overall growth is sluggish, the market is a proven revenue source for a number of major brands, and there have been some nice surprises in the performance of some categories, such as first-aid related antiseptic and antibiotic products. This comprehensive report examines all aspects of the U.S. OTC market, including 5-year sales performance by brand and by marketer for the following categories of products: Antifungals...Published: November 1, 2005 | Price: $2,500.00 – $5,000.00
Some of the biggest-selling biological drugs developed during the first phase of the biotechnology revolution in the 1980s, including human growth hormone (hGH) and insulin, are set to lose patent protection in the United States in 2005 and soon after. This opens up a market currently worth over $30 billion (and growing at over 10% per year) to generic competition, if—and it’s a big if—the regulatory hurdles for these generics can be overcome. Biogeneric is a new term combining biologic...Published: November 1, 2005 | Price: $3,500.00 – $7,000.00
Although, the next 15-20 years will shift a majority of the population into the elderly population group, children will continue to remain the bulk of the dependent population worldwide with 9 in every 10 people falling into a pediatric age range in the less developed regions of Africa, Asia and Latin America. Therefore, the treatment of conditions and diseases affecting pediatrics and the healthy growth of children are vital to providing a solid foundation for healthy adults in the future....Published: October 1, 2005 | Price: $3,500.00 – $7,000.00
Cancer, with its high prevalence and mortality rate, continues to rank among the world's deadliest and most costly diseases. According to the WHO, in 2003, about 25 million people live with cancer and nearly 11 million new cases are diagnosed each year. With advances in protein and cell chemistry, genetics and molecular biology researchers are making continued progress in understanding the disease. Further, cancer drug research is moving from traditional cytotoxic chemotherapies toward higher specificity immunological and biological approaches that...Published: September 1, 2005 | Price: $3,500.00 – $7,000.00
Management of both acute and chronic neurologic diseases can be challenging for both the patient and the health care provider. Many neurologic disorders involve progressive deterioration in physical and mental capabilities, which can be devastating to the patient and the patient’s family. In many respects, neurotherapeutics represent the largest as-yet untapped market in medicine. This Kalorama Information report focuses on several key product segments of neurotherapeutic treatment: Alzheimer’s Disease and Other Dementias Brain and Neurologic Cancers Brain Trauma and Stroke...Published: August 1, 2005 | Price: $2,500.00 – $5,000.00
This market briefing concentrates on the U.S. market for medical nutritional support—in particular, the enteral and parenteral foods. The continuing development of equipment, medical foods, and feeding procedures that secure the nutrition of critically ill patents has greatly improved recovery and survival in select populations. Advances in the effectiveness and safety of nutritional procedures and techniques have evolved from steady improvements, including the use of antibiotic materials, biosensors, wireless communications, and more efficient pumps and controllers. These new developments have...